Mayo Clinic Laboratories and Helix recently announced a collaboration that will provide biopharma customers access to a comprehensive joint laboratory offering for research and development initiatives across the drug development lifecycle. 

The offering will include a full spectrum of testing capabilities that leverages both Helix’s suite of next generation sequencing capabilities and Mayo Clinic Laboratories’ portfolio of more than 3,800 tests and pathology services. Together, Mayo Clinic Laboratories and Helix will provide biopharma customers with full end-to-end laboratory testing support.

Read more about the collaboration.